Signals of inequity in the care pathway: rural lab diagnosis, systemic therapy delays, and RAS mutation differences in metastatic colorectal cancer

• by Adam Ismail, Amandri Dahanayake, Shahid Ahmed, Yagan Pillay, Areej Khatib

• June 2, 2026

Association between EAT-Lancet diet adherence and cancer incidence/mortality: a systematic review and meta-analysis

• by Xinhe Li, Jingqi Chen, Zhanqi Sun, Minyuan Ni, Minmin Fu, Yunshi Tang

• June 1, 2026

Diffuse large B-cell lymphoma presenting as a scalp tumor with skull destruction and neurological symptoms: a case report

• by Ayaka Yasuda, Natsuko Saito-Sasaki, Hirofumi Kawamoto, Yu Sawada

• May 29, 2026

RAS(ON) Inhibitor Doubles Median Overall Survival in Results of Phase 3 Trial for Patients with Metastatic Pancreatic Cancer

At the ASCO annual meeting, Dana-Farber’s Brian Wolpin, MD, MPH, presented positive results from the RASolute 302 trial showing a substantial prolongation of survival for patients with previously treated metastatic pancreatic cancer, regardless of RAS mutation status, taking daraxonrasib, an investigational oral RAS(ON) multi-selective inhibitor, compared with chemotherapy.

• by

• June 1, 2026

• 5 min